Particle News: Latest Gilead Sciences news

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. From Wikipedia

Ebola Pill Shows Promise in Monkey Trials, Raising Hopes for Human Treatment

The antiviral drug obeldesivir demonstrated high survival rates in infected monkeys, offering potential for easier and broader outbreak management.

Stories older than 24h

Annual HIV Prevention Injection Shows Promise in Early Safety Trials

FDA to Decide on First Twice-Yearly HIV Prevention Shot by June

Galapagos Announces Plan to Split Into Two Public Companies by Mid-2025

Lenacapavir Named 'Breakthrough of the Year' for Advancing HIV Prevention

1,000-Year-Old Seed Grows into Medicinal Tree Linked to Biblical Balm

New Biannual HIV Injection Reduces Infection Risk by 96%

Lenacapavir Injection Shows 96% Efficacy in Preventing HIV

Dividend Stocks Primed for Gains as Interest Rates Set to Fall

New HIV Prevention Shot Shows 100% Efficacy in Women

New HIV Drug Could Revolutionize Prevention at Just $40 Annually

Gilead's Lenacapavir Shows 100% Efficacy in HIV Prevention Trial

Gilead Sciences Acquires CymaBay Therapeutics for $4.3 Billion

Gilead's Trodelvy Fails in Lung Cancer Trial, Stock Drops Over 10%